Eli Lilly collaborates with Immunocore on immunotherapy combo; Actelion, Max Planck launch Vaxxilon;

@FierceBiotech: Facing off rivals, Merck looks to expand CINV label on positive PhIII Emend study. Story | Follow @FierceBiotech

@JohnCFierce: These guys at Spinifex are smart--Giant Novartis downs a pain med in $200M-plus buyout of tiny Spinifex. More | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> Eli Lilly ($LLY) and Immunocore have forged an immunotherapy-based clinical trial collaboration to explore the use of Immunocore's lead T-cell receptor-based therapeutic IMCgp100 in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. Release

> Switzerland's Actelion and the Max Planck Society have spun off a new biotech called Vaxxilon to advance synthetic carbohydrate vaccines. Release

> Immune Pharmaceuticals has struck a deal with Yissum, the tech transfer operation of Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet. Release

Medical Device News

@FierceMedDev: ICYMI: FDA gives nod to newest pelvic mesh product, despite ongoing safety issues. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Bard VP touts new study of its Lutonix drug-coated balloon to fight PAD. Article | Follow @VarunSaxena2

@EmilyWFierce: EU stands by crackdown on drug spending in Ireland. FiercePharma story | Follow @EmilyWFierce

> Former OtisMed CEO sentenced to two years in prison for shipping device after FDA rejected it. Article

> Olympus faces new suit from UCLA superbug patient over duodenoscope deviceFacing off rivals, Merck looks to expand CINV label on positive PhIII Emend study. Story

> Wearable, badge-based hand-washing monitoring system improves hospital staff compliance. Report

Pharma News

@FiercePharma: Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug. FiercePharmaMarketing item | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: France's TxCell closes its plant at ANSM urging to avoid contamination. Story | Follow @EricPFierce

@CarlyHFierce: Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say. More | Follow @CarlyHFierce

> Will Mylan boost its Perrigo bid? New securities filing suggests it won't. More

> Tougher regulations force Indian drugmakers to invest or divest. Article

Animal Health News

> Egg prices soar, menu items dropped in wake of historic avian flu. More

> Investors erase Zoetis gains as questions emerge about Valeant's pursuit. Report

> Sorrento nabs key FDA designation for nonopiate drug to treat bone pain in dogs. Item

> Scottish scientists design piglets to resist African swine fever. Story

> Henry Schein expands global reach, taking majority stake in Denmark's Kruuse. Article

Biotech IT News

> Eisai strikes extensive multiyear IT outsourcing deal with Accenture. News

> Google steps up wearables plan with clinical trial-focused wristband. Story

> Analyst: R&D time pressures mean clinical trial tech and automation are finally taking off. More

> Google to pair its cloud-computing power with Broad's analytic tools. Article

> SEC starts pursuit of biotech-focused hacking ring. Report

Pharma Marketing News

> Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug. News

> Should Bristol-Myers cut payer deals to boost melanoma combo over one-drug treatments? More

> Will pharma jump into an EHR app store near you? Don't count on it anytime soon. Story

> Nuedexta maker Avanir taps actor Danny Glover to shed light on little-known neurological condition. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.